Navigation Links
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Date:7/30/2008

activities using the 19-item AD Cooperative Study-Activities of Daily Living scale (ADCS-ADL) demonstrated maintenance of function during the study period, but this was not significantly different from placebo (p=0.18).

The study also demonstrated that once-daily extended-release memantine was well tolerated. The treatment-emergent AEs (TEAEs) profile was similar between the groups; no TEAEs were experienced by greater than or equal to 5% of memantine patients, and at an incidence at least twice that of the placebo group. The most common adverse events occurring at a higher rate than placebo were dizziness (4.7% vs 1.5%), diarrhea (5.0% vs 3.9%), and headache (5.6% vs 5.1%).

About Alzheimer's Disease

Alzheimer's disease is a progressive, degenerative disease of the brain and the most common type of dementia. Dementia is used to describe the progressive loss of cognitive, intellectual, or functional abilities. By 2050, the number of individuals age 65 and over with Alzheimer's disease could range from 11 million to 16 million. Currently, all Alzheimer's disease medications approved in the US other than Namenda belong to a class of agents called cholinesterase inhibitors.

About Namenda

Namenda (memantine HCl) is the first in a class of medications with a unique mechanism of action that focuses on the glutamate pathway, a target for the treatment of Alzheimer's disease. Indicated for the treatment of moderate to severe Alzheimer's disease, the FDA approved Namenda in October 2003 based on three studies of Namenda used alone or in combination with another Alzheimer's disease drug. At present, the recommended dose of Namenda is 10 mg two times a day (20 mg/day).

Namenda is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with Namenda vs placebo (greater than or equal to 5% and higher than placebo) were dizziness, confusion,
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Focal Cryoablation Highlighted in Urology Times Best of AUA Orlando 2008
2. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
3. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
4. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
5. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
6. New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI
7. Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
10. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
11. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/29/2015)... Denmark , July 29, 2015  Ascendis Pharma ... company that applies its innovative TransCon technology to address ... host a conference call on July 30, 2015, at ... from a Phase 2 pediatric study of once-weekly TransCon ... of the top-line results before the market opens on ...
(Date:7/29/2015)... , July 29, 2015 Unilife ... a developer, manufacturer and supplier of injectable drug ... Imperium™ platform of instant patch pumps for insulin. ... multi-day wearable insulin pump that does not require ... is prefilled and pre-assembled like an insulin pen, ...
Breaking Medicine Technology:Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2Unilife Introduces World's First Instant Patch Pump for Insulin 2Unilife Introduces World's First Instant Patch Pump for Insulin 3Unilife Introduces World's First Instant Patch Pump for Insulin 4
...  Provenance Biopharmaceuticals Corp. ("Provenance") announced today the closing ... Enterprises, LLC for the continued development of anti-cancer ... class of molecules called immunocytokines that are being ... cancer.  Immunocytokines, combine the immune stimulating features of ...
... 22, 2011   Marken announced today that Steve Roese ... organization, which will support Marken,s continued investment in their ... world.  Marken is now accelerating construction of several new depot ... existing locations in Singapore , Mexico and ...
Cached Medicine Technology:Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement 2Marken Appoints New Head of Global Quality Assurance 2
(Date:7/30/2015)... ... , ... New research finds some distinct differences in the way mesothelioma behaves ... Surviving Mesothelioma website. , Researchers with the National Institutes of Health, the FDA, ... mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) occurred in ...
(Date:7/30/2015)... ... July 30, 2015 , ... Political unrest is ... according to a new survey by leading international insurance provider Clements Worldwide. The ... medical expenses represented the largest sources of financial losses among respondents. , Twenty-eight ...
(Date:7/30/2015)... ... July 30, 2015 , ... HEALTHCAREfirst , the leading provider of ... that it is hosting a free webinar detailing the 2016 proposed rule from CMS ... and former Vice President of Regulatory Affairs for the National Association for Home Care ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... manufacturing and packaging services for consumer brands, recently completed a consolidation of all ... MD. Previously, the company operated out of two separate locations situated 11 miles ...
(Date:7/29/2015)... ... 2015 , ... Macro Wealth Management (MWM) Presidents have increased the ... program by encouraging their clients to donate their MWM planning fees to the Foundation. ... and Tim Streid, who see charitable giving as an important part of financial planning ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2
... Entire Health Care System More EffectiveWASHINGTON, Jan. 5 ... avoid hospitalization by using special technology provided by the ... to a recent study. "The study showed that ... improves patients, access to care and is easy to ...
... Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... definitive, 3-year distribution agreement with Alliance Lithomobile, a Division ... This agreement supersedes the interim agreement announced on November ...
... Only 17 percent of Spanish-speaking women of childbearing age ... folic acid daily, according to the first- nationally representative ... , Folic acid can prevent neural tube defects ... such as spina bifida and anencephaly, which are more ...
... Jan. 5 Cambrex Corporation (NYSE: ... M. Klosk, President and Chief Executive Officer, will ... January 13, 2009 at 9:00 a.m. PST at ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )A live ...
... new study reveals that the metadherin gene (MTDH) plays ... chemotherapy. The research, published by Cell Press in the ... , identifies MTDH as a promising therapeutic target for ... resist currently available therapeutic regimens and succumb to recurrent ...
... to help healthcare providers put a cap on ... Corporation ( MSC ) will introduce a new ... all healthcare team members who care for hospital ... on medical simulation , the International Meeting ...
Cached Medicine News:Health News:VA Data Show Home Health Technology Improves Access to Care 2Health News:Misonix Announces New HIFU Distribution Agreement for Italy 2Health News:Misonix Announces New HIFU Distribution Agreement for Italy 3Health News:Folic acid survey of Spanish-speaking women finds most are missing benefits, March of Dimes says 2Health News:Gene plays dual role in breast cancers with poor prognosis 2Health News:Medical Simulation Corporation to Introduce Ventilator Associated Pneumonia Program at International Meeting on Simulation in Healthcare 2Health News:Medical Simulation Corporation to Introduce Ventilator Associated Pneumonia Program at International Meeting on Simulation in Healthcare 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: